LD-2 disclosure · 4th Quarter - Report
ARDELYX, INC.
via ARDELYX, INC.
Client
- Name
- ARDELYX, INC.
- Location
- Massachusetts · United States of America
Registrant
- Firm
- ARDELYX, INC.
- Description
- Biopharmaceutical company
- Location
- Freemont, California, United States of America
Lobbying activities
2 issuesHealth Issues
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
LobbyistsPAUL PEREIRA · MATTHEW LASH · KENNETH SPRAGUE · REBECCA WALDROP · ZACHARY KRIBS
TargetedSENATE · HOUSE OF REPRESENTATIVES · Centers For Medicare and Medicaid Services (CMS)
Medicare/Medicaid
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
LobbyistsKENNETH SPRAGUE
TargetedSENATE · HOUSE OF REPRESENTATIVES